Skip to main content
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
As of Mar 30
BusinessUnited Kingdom1 sourcesNeutral

Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment

Late-Breaking Clinical Trial Shows Angiography-derived CathWorks FFRangio Improves Resource Utilization and Reduces Procedure Time ALL-RISE One-year Results Simultaneously Published in the New England Journal of Medicine NEW ORLEANS, March 29, 2026 /PRNewswire/ -- Today at the American...

PN
pr newswire uk
via Pr Newswire Uk
Landmark ALL-RISE® Trial Results Presented at ACC.26: CathWorks FFRangio Demonstrates Similar Clinical Outcomes to Invasive Wire-based Physiology Assessment

Source Verification

Corroboration Score: 1

This story was independently reported by 1 sources. Click any source to read the original article.

Comments

0 comments
Be respectful and constructive.
Loading comments...